Gilead Sciences has priced senior unsecured notes worth $2 billion in a registered public offering. The notes consist of $1 billion in 5.250% senior notes maturing in 2033 and $1 billion in 5.550% senior notes maturing in 2053. The offering is set to close on September 14, 2023, subject to customary closing conditions. The proceeds will be used for general corporate purposes. Barclays Capital and Citigroup Global Markets are the lead joint book-running managers for the offering.
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053. The offering is expected to close September 14, 2023, subject to customary closing conditions.
Gilead intends to use the net proceeds from this offering for general corporate purposes.
Barclays Capital Inc. and Citigroup Global Markets Inc. are acting as lead joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead’s effective shelf registration statement on Form S-3 (File No. 333-273745), copies of which may be obtained from:
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace
